Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE

https://doi.org/10.20996/1819-6446-2012-8-1-4-16

Full Text:

Abstract

Aim. To estimate in a 12-month study mortality and frequency of recurrent cardiovascular events, dynamics of neurological deficit and endothelial dysfunction in patients with the first-time ischemic stroke treated with simvastatin 40 mg/day in acute period of the disease. Materials and methods. The efficacy of high-dose simvastatin (40 mg/day) therapy initiated in acute stage of ischemic stroke was evaluated in 12-month comparative randomized study. Patients of the first group (n=97) received standard stroke therapy , and patients of the second group (n=86) also received standard treatment and simvastatin additionally. Combined endpoint (cardiovascular death + recurrent cardiovascular events + necessity of readmission), dynamics of neurological status and endothelial function were considered.  Results. Primary combined endpoint was achieved in 66 cases in the first group (68.04%) and in 47 (54.65%) in the second one (p=0.043). Neurological status evaluated by National Institutes of Health Stroke Scale (NIHSS), Mini-Mental State Examination (MMSE) scale, and Scandinavian scales had a faster positive dynamics in patients receiving simvastatin. The same patients revealed more intense and quick decrease in desquamated plasma endotheliocytes. Conclusion. Simvastatin 40 mg/day prescribed along with neuroprotective and antihypertensive treatment in acute stage of ischemic stroke leads to lowering of recurrent cardiovascular events number, positive dynamics of neurological status, regression of endothelial dysfunction reflected by significant decrease in number of circulating desquamated endotheliocytes.

About the Authors

V. V. Yakusevich
Yaroslavl State Medical Academy
Russian Federation

PhD, MD, Professor , Chair of clinical pharmacology



A. Yu. Malygin
Yaroslavl Municipal Clinical Hospital №8
Russian Federation

PhD, MD, Head of resuscitation unit



S. V. Lychenko
Yaroslavl State Medical Academy
Russian Federation

MD, PhD. student, Chair of clinical pharmacology



A. S. Petrochenko
Yaroslavl State Medical Academy
Russian Federation
PhD, MD, assistant of the same Chair


A. V. Kabanov
Yaroslavl State Medical Academy
Russian Federation
PhD, MD, assistant of the same Chair


References

1. Bonita R. Stroke prevention: a global perspective. In: Norris JW, Hachinsky V, eds. Stroke Prevention. New York, NY: Oxford University Press; 2001:259-74.

2. World Health Organization (WHO). The World Health Report. Geneva: WHO; 1999.

3. American Heart Association. 2001 Heart and stroke statistical update. Dallas, Texas: American Heart Association; 2001.

4. Bonita R. Epidemiology of stroke. Lancet 1992;339:342-4

5. Kalashnikova L.A., Konovalov R.N.,Dobrynina L.A. Ischemic stroke in spontaneous dissection of the isolated posterior cerebral arteries at a young age. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2009; 109 (5) suppl 2: 3–10. Russian (Калашникова Л.А., Коновалов Р.Н., ДобрынинаЛ.А. Ишемический инсульт при спонтанной изолированной диссекции задней мозговой артерии в молодом возрасте. Журнал неврологии и психиатрии им. С.С. Корсакова 2009; 109 (5) приложение 2: 3–10).

6. Damulin I.V., Parfenov V.A., Skoromets A.A., Yakhno N.N. Circulatory disorders in the brain and spinal cord. In: Yakhno N.N., editor.Diseases ofthe nervous system. Guide for physicians. Vol 1. Moscow: Meditsina; 2005: 231–302. Russian (Дамулин И.В., Парфенов В.А., Скоромец А.А., Яхно Н.Н. Нарушения кровообращения в головном и спинном мозге. В: Яхно Н.Н., редактор. Болезни нервной системы. Руководство для врачей. Том 1. М.: Медицина; 2005: 231–302).

7. Suslinа Z.A. Vascular disease of the brain in Russia: reality and prospects of solving the problem. MaterialsXIIІ International Conference on "Modern trends in neurology,"April 27-29, 2001, Sudak (Ukraine); 2011. Russian (Суслина З.А. Сосудистые заболевания головного мозга в России: реальность и перспективы решения проблемы. Материалы XIIІ Международной конференции «Актуальные направления в неврологии», 27-29 апреля 2001 г., Судак (Украина). Судак; 2011).

8. VibersD. Feigin, B., Brown R. Stroke: Clinical Manual. Moscow: Binom; 2005. Russian (ВиберсД., Фей- гин В., Браун Р. Инсульт: Клиническое руководство. М.: Бином; 2005).

9. Sacco R.L., Adams R., Albers G. et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American StrokeAssociation Council on Stroke: Co–Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577 – 617.

10. Bhatt D.L., Steg P.G., Ohman E.M. et al., for the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180–189.

11. Suslina Z.A., Tanashyan M.M., Lagoda O.V. Atherosclerosis and ischemic cerebrovascular accidents. Aterotromboz 2009; (2): 60-67. Russian (Суслина З.А., Танашян М.М., Лагода О.В. Атеросклероз и ишемические нарушения мозгового кровообращения. Атеротромбоз 2009; (2): 60-67).

12. Cooke J.P, Tsao P.S. Is NO an endogenous antiathero-genic molecule? Arterioscler Thromb 1994; 14: 653-655.

13. Golovchenko, Y., Treschinskaya M.A. Pathogenetic features of the local regulation of cerebral blood flow in endothelial dysfunction. Materials XIIІ International Conference on "Modern trends in neurology," April 27-29, 2001, Sudak (Ukraine); 2011. (Головченко Ю.И., Трещинская М.А. Патогенетические особенности локальной регуляции мозгового кровообращения при эндотелиальной дисфункции. Материалы XIIІ Международной конференции «Актуальные направления в неврологии», 27-29 апреля 2001 г., Судак (Украина). Судак; 2011).

14. Hirase T., Node K. Endothelial Dysfunction as a Cellular Mechanism for Vascular Failure. Am J Physiol Heart Circ Physiol 2011 [Epub ahead of print]

15. Sakurai K., Isahaya K., Takaishi S. et al. Effects of early statin treatment on inflammatory biomarkers and clinical deterioration in patients with acute ischemic stroke. Rinsho Shinkeigaku 2011;51(1):6-13.

16. Vane J.R., Anggard E.E., Batting R.M. Regulatory functions of the vascular endothelium. N Engl J Med 1990: 323: 27-36.

17. Vanhoutte P.M. How to assess endothelial function in human blood vessels.J Hypertens 1999; 17(8): 1047-1058.

18. Davies M.J., Thomas А.С. Plaque fissuring — the cause of acute myocardial infarction, sudden ischemic death, and creshendo angina. Brit Heart J 1985: 53 (4): 363-373.

19. Falk E., Shah P.K., Faster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.

20. Fuster V., Lewis A. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994: 90: 2126-2146.

21. Calabrт P., Golia E., Yeh E.T. Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches. Curr Pharm Biotechnol 2011 [Epub ahead of print]

22. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011;42;227-276.

23. Amarenco P., Bogousslavsky J., Callahan A. et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 335;549-559

24. Bianco M., Nombela F., Castellanos M. et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 2007; 69: 904-910.

25. Amarenco P., Labreuche J., Lavalle'e P., Touboul P-J. Statin in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke 2004; 35: 2902-9.

26. Plenge J.K., Hernandez T.L., Weil K.M. et al. Simvastatin Lowers C-Reactive Protein Within 14 Days An EffectIndependent of Low-Density Lipoprotein Cholesterol Reduction. Circulation 2002;106:1447-52.

27. Fisher M. Injuries to the vascular endothelium: vascular wall and endothelial dysfunction. Rev Neurol Dis 2008; 5 Suppl 1:S4-11.

28. Dovgalevskiy P.Ya., Furman N.V. Stabilization of atherosclerotic plaques — the mainstay of treatment of acute coronary syndrome. Atmosfera. Kardiologiya 2004; (3): 6-10. Russsian (ДовгалевскийП.Я., Фурман Н.В. Стабилизация атеросклеротической бляшки — основа лечения острого коронарного синдрома. Атмосфера. Кардиология 2004; (3): 6-10).

29. Hladovec J. Circulating endothelial cells as a sign of vessel wall lesions. Рhysiol Bohemoslov 1978; 27: 140-144.

30. Berkovich O.A., Belyaeva O.D., Bazhenova E.A. et al. Effect of statins on the functional state of the vascular endothelium in patientswith coronary heart disease. RusskiyMeditsinskiy Zhurnal2002;10(19): 874-877. Russian (Беркович О.А., Беляева О.Д., Баженова Е.А. и др. Влияние статинов на функциональное состояние эндотелия сосудов у больных ишемической болезнью сердца. Русский Медицинский Журнал 2002; 10(19): 874-877.

31. Bory M., Sampol J., Yvorra S. et al. Detection des cellules endotheliales circulantes: un nouveau test diagniostique de l` angor de repos. Arch Mal Coeur Vaiss 1995;88(12):1827-1831.

32. Kukharchuk V.V. Lipid infiltration theory. Does changing the script? Kardiologicheskiy vestnik 2009; Volume I (XVI) (1): 63–66. Russian (Кухарчук В.В. Липидно-инфильтрационная теория. Действительно ли меняется сценарий? Кардиологический вестник 2009; том I (XVI) (1): 63–66).

33. Shal'nova S.A., Deev A.D., Oganov R.G. Factors influencing the mortality from cardiovascular disease. Kardiovaskulyarnaya Terapiya i Profilaktika 2005; 4 (1): 4–9. Russian (Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика 2005; 4 (1): 4–9).

34. Nassief A., Marsh J.D. Statin therapy for stroke prevention. Stroke 2008;39(3):1042-8.

35. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.

36. Blauw G.J., Lagaay A.M., Smelt A.H.M., Westendorp R.G.J. Stroke, statins, and cholesterol: a metaanalysis ofrandomized, placebocontrolled, doubleblind trials withHMG-CoAreductase inhibitors. Stroke 1997;28:946-50.

37. Martinez-Ramirez S., Delgado-Mederos R., Marin R. et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis forischemic stroke:results from a case-control study and a meta-analysis. J Neurol 2011; 259(1): 111-8.

38. Henyan N.N., Riche D.M., East H.E., Gann P.N. Impact of Statins on Risk of Stroke: A Meta-Analysis. The Annals of Pharmacotherapy 2007;41(12):1937-1945.

39. Manktelow B.N., Potter J.F. Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence Stroke 2009; 40: e622-e623.

40. Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923-32.

41. Switzer J.A., Hess D.C. Statin therapy for coronary heart disease and its effect on stroke. Curr Atheroscler Rep 2006; 8: 337-42.

42. Underhill H.R., Yuan C., Zhao X.Q. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J 2008; 155: e581-e588.

43. Fuentes B., Martínez-Sánchez P., Díez-Tejedor E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009;27 Suppl 1:126-33.

44. Tsai N.W., Lin T.K., Chang W.N. et al. Statin pre-treatment is associated with lower platelet activity and favorable outcome in patientswith acute non-cardio-embolic ischemic stroke.CritCare2011;15(4):R163.

45. Bull T.M., Golpon H. et al. Circulating endothelial cells in pulmonary hypertension. Thromb Haemost 2003;90(4):698-703.

46. Berkovich O.A., Ryabova T.S., Bazhenova E.A i dr. Effect of angiotensin-converting enzyme Kvadroprila on the functional state of vascular endothelium in patients with coronary heart disease with different genotypes of angiotensin-converting enzyme gene. Mezhdunarodnyy Meditsinskiy Zhurnal 2003; 6(2): 152-154. Russian (Беркович О.А., Рябова Т.С., Баженова Е.А и др. Влияние ингибитора ангиотензин-превращающего фермента Квадроприла на функциональное состояние эндотелия сосудов у больных ишемической болезнью сердца с различными генотипами гена ангиотензин-превращающего фермента. Международный Медицинский Журнал 2003; 6(2): 152-154).

47. Kumar S., Savitz S., Schlaug G. et al. Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk. Neurology 2006; 66: 1153-8. (13)

48. Almazov V.A., Sitnikov M.Yu., Ivanov S.G. et al. Carvedilol in the treatment of patients with chronic heart failure: clinical and metabolic effects. Serdechnaya Nedostatochnost' 2001; 2(2): 68-70. Russian (Алмазов В.А., Ситников М.Ю., Иванов С.Г. и др. Карведилол в лечении больных хронической сердечной недостаточностью: клинические и метаболические эффекты. Сердечная недостаточность 2001; 2(2): 68-70).

49. Boos C.J., Soor S.K., Kang D., Lip G.Y.N. Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes. EurHeartJ 2007; 28(9): 1092-1101.

50. Hladovec J., Prerovsky I., Stanek V., Fabian J. Circulating endothelial cells in acute myocardial infarction and angina pectoris. Klin Wochenschr 1978; 56: 1033-6. Received/Поступила 29.11.2011 Accepted/Принята в печать 05.12.2011


For citation:


Yakusevich V.V., Malygin A.Yu., Lychenko S.V., Petrochenko A.S., Kabanov A.V. THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE. Rational Pharmacotherapy in Cardiology. 2012;8(1):4-16. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-1-4-16

Views: 463


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)